Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
BMY [NYSE]
Bristol-Myers Squibb Company
Healthcare | Drug Manufacturers - Major | USA
financial highlights | statements
IndexS&P 500 P/E50.07 EPS (ttm)0.88 Insider Own0.15% Shs Outstand1.64B Perf Week4.38%
Market Cap72.37B Forward P/E20.69 EPS next Y2.13 Insider Trans4.67% Shs Float1.64B Perf Month5.08%
Income1.47B PEG5.27 EPS next Q0.44 Inst Own69.00% Short Float1.80% Perf Quarter21.11%
Sales16.20B P/S4.47 EPS this Y-46.16% Inst Trans2.18% Short Ratio2.93 Perf Half Y41.63%
Book/sh8.31 P/B5.30 EPS next Y17.68% ROA4.80% Target Price39.30 Perf Year39.87%
Cash/sh1.54 P/C28.57 EPS next 5Y9.50% ROE9.78% 52W Range30.05 - 45.59 Perf YTD37.82%
Dividend1.40 P/FCF21.94 EPS past 5Y12.31% ROI6.22% 52W High-3.36% Beta0.44
Dividend %3.18% Quick Ratio0.98 Sales past 5Y2.44% Gross Margin73.03% 52W Low46.61% ATR0.95
Employees28000 Current Ratio1.20 Sales Q/Q-27.04% Oper. Margin6.09% RSI (14)67.84 Volatility3.69% 2.13%
OptionableYes Debt/Eq0.58 EPS Q/Q-42.93% Profit Margin10.14% Rel Volume1.01 Prev Close44.06
ShortableYes LT Debt/Eq0.48 EarningsApr 25 BMO Payout156.92% Avg Volume10.07M Price44.06
Recom2.40 SMA207.07% SMA508.39% SMA20025.70% Volume0 Change0.00%
26-Apr-13Reiterated MKM Partners Sell $26 → $29
15-Apr-13Reiterated Barclays Equal Weight $33 → $42
25-Jan-13Reiterated UBS Neutral $34 → $36
09-Jan-12Reiterated Barclays Capital Overweight $34 → $36
19-Oct-11Initiated MKM Partners Sell $26
27-Jun-11Reiterated UBS Neutral $28 → $30
31-Mar-11Downgrade Jefferies Buy → Hold $28.50
28-Mar-11Reiterated Barclays Capital Overweight $28 → $30
22-Sep-10Reiterated Deutsche Bank Buy $28 → $31.50
01-Sep-10Reiterated UBS Neutral $26 → $27
31-Aug-10Upgrade Jefferies Hold → Buy $28.80 → $30
12-Mar-10Initiated Jefferies & Co Hold $27
16-Dec-09Initiated UBS Neutral
09-Oct-09Initiated Wells Fargo Outperform
03-Apr-09Downgrade Bernstein Outperform → Mkt Perform
10-Dec-08Upgrade Citigroup Hold → Buy $25
07-Aug-08Reiterated Argus Buy $30 → $27
18-Jul-08Initiated Citigroup Hold $23
25-Jun-08Initiated JP Morgan Neutral
04-Jun-08Downgrade Cowen & Co Outperform → Neutral
22-May-13 08:35AM  Ahead of the Bell: Analyst upgrades Bristol-Myers AP
05:33AM  Immune system cancer drugs tipped to be a $35 bln market at Reuters
21-May-13 08:50PM  Final Glance: Pharmaceuticals companies AP
03:13PM  Bristol-Myers Squibb's Management Presents at UBS Global Healthcare Services Conference (Transcript) Seeking Alpha
03:05PM  Roche, Reloaded at Investopedia
02:28PM  The Top 3 Diseases Caused by Stress at Motley Fool
01:16PM  Midday Glance: Pharmaceuticals companies AP
11:45AM  After A Big Rally, Pfizer Might Need Some Rest at Investopedia
11:37AM  Cramer: Buy BioMarin Pharma, Bristol-Myers Squibb, Asbury Automotive, But Sell These 2 Stocks at Wall St. Cheat Sheet
10:36AM  Early Glance: Pharmaceuticals companies AP
09:40AM  Bristol-Myers Squibb Director Sells More Than 215K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
06:00AM  Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA at TheStreet
20-May-13 06:26PM  Cramer's Watch List Ahead of Big Cancer Conference at CNBC
06:25PM  [video] The War Against Cancer at CNBC
06:05PM  Final Glance: Pharmaceuticals companies AP
05:01PM  Teva Bets on Reformulating Old Drugs as Investors Say Show Me at Bloomberg
04:34PM  Bristol Myers Squibb And The New Wave Of Cancer Drugs at Seeking Alpha
01:44PM  Will Amgen's Novel Drug Revolutionize Cancer Treatment? at Motley Fool
01:17PM  Midday Glance: Pharmaceuticals companies AP
01:03PM  5 Drugs Stocks On The Rise at TheStreet
12:01PM  1 Pioneering Device to Jump-Start the Cardiovascular Industry at Motley Fool
10:33AM  Early Glance: Pharmaceuticals companies AP
10:03AM  Shire advances after report renews takeover speculation at theflyonthewall.com
09:01AM  [video] Monday's Market Roadmap at CNBC
06:30AM  Leerink estimates Shire takeout value at least $110 per share at theflyonthewall.com
06:25AM  Shire may return cash to thwart takeover, Daily Mail reports theflyonthewall.com
19-May-13 09:10PM  Shades Of 1999 at Seeking Alpha
04:43PM  Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin at Seeking Alpha
11:00AM  Pick Your Poison: Overweight or High Cholesterol at Motley Fool
08:11AM  PRESS DIGEST - Sunday British business - May 19 at Reuters
18-May-13 12:45PM  1 Giant Leap for MannKind at Motley Fool
17-May-13 08:52PM  Oncothyreon A Speculative Buy at Seeking Alpha
06:03PM  Final Glance: Pharmaceuticals companies AP
05:00PM  Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner at TheStreet
01:33PM  Midday Glance: Pharmaceuticals companies AP
10:25AM  Early Glance: Pharmaceuticals companies AP
08:53AM  Analysts' Actions: AMAT ARUN BMY DE WSM TheStreet
07:25AM  Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy at Seeking Alpha
16-May-13 07:15PM  [$$] AbbVie Is Good Medicine at Barrons.com
06:03PM  Most active New York Stock Exchange-traded stocks AP
06:03PM  Final Glance: Pharmaceuticals companies AP
05:05PM  Cheerleaders: Look Beyond Pharma For Jobs YCharts
04:31PM  InPlay: Bristol-Myers announces intention to voluntarily delist preferred stock Briefing.com
04:30PM  Bristol-Myers Squibb Announces Intention to Voluntarily Delist Preferred Stock Business Wire
04:17PM  Bristol-Myers Drug Cocktail Stymies Melanoma Tumors at Bloomberg
02:09PM  [video] Biotech's Next Big Thing ASCO II at TheStreet
02:09PM  [video] Biotech's Next Big Thing -- ASCO II at TheStreet
02:04PM  Analysts: Bristol-Myers Shares Will Give Back Gains and 3 More Research Notes to Check Out at Wall St. Cheat Sheet
01:41PM  Four Stocks to Own Regardless of a Pullback at Motley Fool
01:33PM  [video] New Cancer Drugs Harness Power of Immune System at MarketWatch
01:29PM  Most active New York Stock Exchange-traded stocks AP
01:29PM  Midday Glance: Pharmaceuticals companies AP
01:17PM  This Sector Is No Bargain at Motley Fool
10:36AM  Early Glance: Pharmaceuticals companies AP
09:20AM  Futures Edge Lower; Kohl's Pops After Earnings, Wal-Mart Falls at Barrons.com
08:00AM  Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha
06:24AM  5 Stock Trades for S&P 1,700 at TheStreet
15-May-13 09:01PM  Melanoma Treatment Harnesses Immune System to Combat Cancer Cells at New York Times +5.05%
07:10PM  Cancer Meeting Highlights the Good and Bad of the Immune System at Motley Fool
07:09PM  With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What at Forbes
06:25PM  InPlay: Bristol-Myers to hold investor teleconference to discuss ASCO highlights Briefing.com
06:10PM  Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights Business Wire
06:04PM  Most active New York Stock Exchange-traded stocks AP
06:02PM  Final Glance: Pharmaceuticals companies AP
06:00PM  Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
06:00PM  Bristol-Myers Drug Cocktail Stymies Melanoma Tumors at Bloomberg
06:00PM  ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors at TheStreet
05:59PM  Roche immunotherapy shows response over range of cancers at Reuters
05:59PM  Bristol melanoma drug combo marks new advance in immunotherapy at Reuters
05:19PM  4 Healthcare Stock Stories Prescribed for Investors at Wall St. Cheat Sheet
05:15PM  Today's 3 Best Stocks at Motley Fool
04:59PM  Why Bristol-Myers Is Soaring at Motley Fool
04:00PM  Pediatric Approval for MDCO/BMY's Recothrom Zacks
03:20PM  Bristol-Myers shares jump ahead of melanoma trial data at Reuters
02:10PM  Busy Day For Bristol-Myers Options As Shares Sprint Higher at Seeking Alpha
01:27PM  NYSE stocks posting largest percentage increases AP
01:27PM  Most active New York Stock Exchange-traded stocks AP
01:26PM  Midday Glance: Pharmaceuticals companies AP
01:03PM  5 Stocks Boosting The Drugs Industry Higher at TheStreet
11:23AM  Bristol-Myers Targets Heart-Failure Drugs in R&D Effort at Bloomberg
10:43AM  Bristol-Myers Squibb Reaches New 52-Week High (BMY) at TheStreet
10:24AM  Early Glance: Pharmaceuticals companies AP
09:12AM  Dirty Medicine at Fortune
07:55AM  3 Pharmaceuticals For Attractive Dividends at Seeking Alpha
14-May-13 06:16PM  Why This Pharma Giant Doesn't Look Good Now at Motley Fool
06:02PM  Final Glance: Pharmaceuticals companies AP
04:20PM  Amgen to Set Up JV in China Zacks
03:28PM  Don't Get Too Excited About This Cancer Drug Yet at Motley Fool
03:18PM  Bristol-Myers Squibb to Present at UBS Global Health Care Conference Business Wire
02:16PM  Should You Buy Stock in Gilead After the Earnings Miss? at Motley Fool
02:11PM  Midday Glance: Pharmaceuticals companies AP
12:30PM  A Buyout Could Send This Leading Agriculture Stock Up 25% StreetAuthority Network
12:30PM  A Buyout Could Send This Leading Agriculture Stock Up 25%
10:37AM  Early Glance: Pharmaceuticals companies AP
10:10AM  Will Investors Take the Plunge Over the Patent Cliff With Humira? at Motley Fool
01:58AM  Big Pharma's Biggest Losers at Motley Fool
13-May-13 06:02PM  Final Glance: Pharmaceuticals companies AP
01:18PM  Midday Glance: Pharmaceuticals companies AP
10:55AM  Buying the Pharma Dips at Motley Fool
10:23AM  Early Glance: Pharmaceuticals companies AP
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CORNELIUS JAMES MDirectorMay 17Option Exercise22.14205,9964,560,751957,820May 20 04:17 PM
CORNELIUS JAMES MDirectorMay 17Sale42.98215,9969,283,708741,824May 20 04:17 PM
CORNELIUS JAMES MDirectorMay 16Sale43.2410,000432,400751,824May 20 04:17 PM
DANIELS BRIANSVP Global Dev & Med AffairsMay 08Sale39.9315,000598,95063,239May 08 04:25 PM
CORNELIUS JAMES MDirectorMay 08Sale39.7810,000397,800761,824May 09 04:19 PM
CORNELIUS JAMES MDirectorMay 07Sale39.9110,000399,100771,824May 09 04:19 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 04Option Exercise0.0013,9890582,457May 07 06:29 PM
CORNELIUS JAMES MDirectorMay 02Sale39.8510,000398,500781,824May 02 05:01 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000025,754May 02 04:23 PM
CORNELIUS JAMES MDirectorMay 01Sale39.6610,000396,600791,824May 02 05:01 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 30Option Exercise24.98305,9057,641,575459,398May 01 05:58 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 30Sale39.61353,50914,004,254105,889May 01 05:58 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 30Sale39.652,29791,0769,091May 01 05:58 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 29Option Exercise24.0373,3901,763,821258,411May 01 05:58 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 29Sale39.92104,9184,188,026153,493May 01 05:58 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 29Sale39.9745,7831,829,9479,550May 01 05:58 PM
CORNELIUS JAMES MDirectorApr 26Sale40.1210,000401,200801,824Apr 29 04:22 PM
CORNELIUS JAMES MDirectorApr 25Sale40.3410,000403,400811,824Apr 29 04:22 PM
CORNELIUS JAMES MDirectorApr 17Sale40.7510,000407,500821,824Apr 18 04:18 PM
CORNELIUS JAMES MDirectorApr 16Sale40.8210,000408,200831,824Apr 18 04:18 PM
CORNELIUS JAMES MDirectorApr 11Sale41.3110,000413,100841,824Apr 11 05:13 PM
CORNELIUS JAMES MDirectorApr 10Sale40.9910,000409,900851,824Apr 11 05:13 PM
CORNELIUS JAMES MDirectorApr 02Sale41.5910,000415,900861,824Apr 02 05:03 PM
CORNELIUS JAMES MDirectorApr 01Sale41.0910,000410,900871,824Apr 02 05:03 PM
CORNELIUS JAMES MDirectorMar 27Sale40.6810,000406,800881,218Mar 28 04:31 PM
CORNELIUS JAMES MDirectorMar 26Sale40.6210,000406,200891,218Mar 28 04:31 PM
CORNELIUS JAMES MDirectorMar 21Sale39.7810,000397,800901,218Mar 22 04:16 PM
CORNELIUS JAMES MDirectorMar 20Sale39.7810,000397,800911,218Mar 22 04:16 PM
Cuss Francis MSVP ResearchMar 13Option Exercise23.8084,9522,021,810264,874Mar 14 04:26 PM
Cuss Francis MSVP ResearchMar 13Sale38.4769,7132,681,859195,161Mar 14 04:26 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 13Sale38.513,409131,28133,727Mar 14 04:26 PM
CORNELIUS JAMES MDirectorMar 13Sale38.3410,000383,400921,218Mar 14 04:26 PM
CORNELIUS JAMES MDirectorMar 12Sale38.0210,000380,200931,218Mar 14 04:26 PM
CORNELIUS JAMES MDirectorMar 08Sale37.4110,000374,100941,218Mar 11 04:28 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 07Option Exercise0.00330,1600739,611Mar 11 04:33 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 07Option Exercise0.002,528012,445Mar 11 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 07Option Exercise0.0069,5420142,348Mar 11 04:37 PM
Cuss Francis MSVP ResearchMar 07Option Exercise0.0045,0170197,975Mar 11 04:40 PM
Caldarella Joseph CSVP & ControllerMar 07Option Exercise0.0020,808078,584Mar 11 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 07Option Exercise0.0081,2030228,185Mar 11 04:44 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 07Option Exercise0.0042,070094,942Mar 11 04:43 PM
Caforio GiovanniPres., US PharmaceuticalsMar 07Option Exercise0.0015,482068,493Mar 11 04:47 PM
Cazala Beatrice JEVP Commercial OperationsMar 07Option Exercise13.77179,6782,474,000387,221Mar 11 04:47 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 07Option Exercise0.0021,975063,619Mar 11 04:50 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 07Option Exercise0.0014,425025,308Mar 11 04:50 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 07Option Exercise0.0015,169040,764Mar 11 04:50 PM
SIGAL ELLIOTEVP, CSO & President R&DMar 07Option Exercise0.00132,3900247,731Mar 11 04:50 PM
CORNELIUS JAMES MDirectorMar 07Sale37.6710,000376,700951,218Mar 11 04:28 PM
Cazala Beatrice JEVP Commercial OperationsMar 07Sale37.6183,7503,149,838266,245Mar 11 04:47 PM
Cazala Beatrice JEVP Commercial OperationsMar 06Option Exercise0.003,5950208,876Mar 07 04:05 PM
SIGAL ELLIOTEVP, CSO & President R&DMar 04Option Exercise0.007,4530119,206Mar 05 04:55 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 04Option Exercise0.003,9800148,465Mar 05 04:54 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 04Option Exercise0.001,870053,569Mar 05 04:54 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 04Option Exercise0.007,4530412,524Mar 05 04:54 PM
SIGAL ELLIOTEVP, CSO & President R&DMar 03Option Exercise0.0046,3650135,794Mar 05 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.002,487073,563Mar 05 04:24 PM
Cuss Francis MSVP ResearchMar 03Option Exercise0.003,7530154,351Mar 05 04:26 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.002,379058,761Mar 05 04:26 PM
Caforio GiovanniPres., US PharmaceuticalsMar 03Option Exercise0.001,851053,701Mar 05 04:26 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.002,422042,547Mar 05 04:27 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.001,851026,159Mar 05 04:27 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.001,936011,594Mar 05 04:27 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.004,7930146,271Mar 05 04:54 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.002,691052,701Mar 05 04:54 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.0010,3440409,335Mar 05 04:54 PM
Caforio GiovanniPres., US PharmaceuticalsFeb 27Sale37.0812,150450,52251,850Feb 27 04:08 PM
CORNELIUS JAMES MDirectorFeb 26Sale36.4410,000364,4001,061,218Feb 27 04:08 PM
CORNELIUS JAMES MDirectorFeb 25Sale36.7110,000367,1001,071,218Feb 27 04:08 PM
Caldarella Joseph CSVP & ControllerFeb 20Option Exercise25.1340,3081,012,92093,967Feb 20 04:12 PM
Caldarella Joseph CSVP & ControllerFeb 20Sale36.8737,5851,385,75956,382Feb 20 04:12 PM
CORNELIUS JAMES MDirectorFeb 13Sale36.1510,000361,5001,101,218Feb 13 05:09 PM
CORNELIUS JAMES MDirectorFeb 12Sale36.6810,000366,8001,111,218Feb 13 05:09 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 11Option Exercise28.1116,875474,35639,572Feb 11 04:08 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 11Sale36.9715,264564,35924,308Feb 11 04:08 PM
SIGAL ELLIOTEVP, CSO & President R&DFeb 08Option Exercise20.81266,0825,536,826314,134Feb 11 04:08 PM
SIGAL ELLIOTEVP, CSO & President R&DFeb 08Sale36.79224,7058,266,89789,429Feb 11 04:08 PM
CORNELIUS JAMES MDirectorFeb 07Sale36.4210,000364,2001,121,218Feb 08 04:30 PM
CORNELIUS JAMES MDirectorFeb 06Sale36.5110,000365,1001,131,218Feb 08 04:30 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 05Option Exercise23.1419,310446,833158,258Feb 05 04:18 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 05Sale36.8716,780618,679141,478Feb 05 04:18 PM
CAMPBELL LEWIS BDirectorFeb 04Option Exercise25.513,50089,2853,500Feb 05 04:06 PM
von Autenried PaulSVP & CIOFeb 04Option Exercise25.5756,2121,437,22790,425Feb 05 04:18 PM
von Autenried PaulSVP & CIOFeb 04Sale36.6750,3001,844,50140,125Feb 05 04:18 PM
CAMPBELL LEWIS BDirectorFeb 04Sale36.773,500128,6950Feb 05 04:06 PM
DANIELS BRIANSVP Global Dev & Med AffairsJan 31Sale36.2212,000434,64050,010Jan 31 04:54 PM
GLIMCHER LAURIE H M.D.DirectorJan 30Option Exercise25.6011,000281,56011,000Jan 30 04:16 PM
GLIMCHER LAURIE H M.D.DirectorJan 30Sale36.4011,000400,4000Jan 30 04:16 PM
CORNELIUS JAMES MDirectorJan 29Sale36.5310,000365,3001,141,218Jan 30 04:06 PM
Caforio GiovanniPres., US PharmaceuticalsJan 28Option Exercise28.6722,500645,07584,350Jan 28 04:32 PM
Caforio GiovanniPres., US PharmaceuticalsJan 28Sale36.1920,350736,46764,000Jan 28 04:32 PM
CORNELIUS JAMES MDirectorJan 28Sale36.4310,000364,3001,151,218Jan 30 04:06 PM
CORNELIUS JAMES MDirectorJan 25Sale36.3210,000363,2001,161,218Jan 28 04:11 PM
CORNELIUS JAMES MDirectorJan 24Sale35.7810,000357,8111,171,218Jan 28 04:11 PM
CORNELIUS JAMES MDirectorJan 17Sale34.3310,000343,3001,181,218Jan 18 04:40 PM
CORNELIUS JAMES MDirectorJan 16Sale34.3310,000343,3001,191,218Jan 18 04:40 PM
CORNELIUS JAMES MDirectorJan 08Sale33.5810,000335,8001,201,218Jan 09 04:15 PM
CORNELIUS JAMES MDirectorJan 07Sale33.4010,000334,0001,211,218Jan 09 04:15 PM
CORNELIUS JAMES MDirectorJan 04Sale33.2610,000332,6001,221,218Jan 07 04:25 PM
Caforio GiovanniPres., US PharmaceuticalsJan 03Option Exercise0.007,500064,760Jan 07 04:25 PM
CORNELIUS JAMES MDirectorJan 03Sale32.9810,000329,8001,231,218Jan 07 04:25 PM
open in yahoo | open in reuters | open in google